Anavex publishes new data on oral blarcamesine in Alzheimer’s trial

Anavex Life Sciences has published a preprint of its Phase IIb/III trial of oral blarcamesine, presenting a precision-medicine approach in Alzheimer’s disease, according to the company. The publication is hosted on medRxiv and is under submission to a peer-reviewed journal. The company claims that up to ~70% of participants in the defined genetic population showed […] The post Anavex publishes new data on oral blarcamesine in Alzheimer’s trial appeared first on Longevity.Technology.